Rznomics' RZ-001 Gene Therapy Wins Positive EU Orphan Drug Opinion for Glioma
核心洞察
The EMA's Committee for Orphan Medicinal Products adopted a positive opinion on September 28 recommending orphan drug designation for Rznomics (搜索)' RZ-001 in glioma (搜索).
The committee judged RZ-001 capable of delivering significant benefit despite existing approved therapies, citing clinical responses in recurrent glioblastoma (搜索) patients.
RZ-001 is an adenovirus type 5-based gene therapy carrying an RNA replacement enzyme targeting hTERT mRNA plus an HSV-TK gene.
South Korea's Rznomics (搜索) has cleared the first regulatory hurdle toward orphan drug designation in Europe for its anti-cancer gene therapy RZ-001. The European Medicines Agency (搜索)'s Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on September 28 recommending orphan drug designation for RZ-001 in the treatment of glioma (搜索).
The recommendation is not final. The COMP opinion must still be approved by the European Commission, but the committee's formal recognition that RZ-001 meets the designation criteria raises the likelihood of final approval.
Significant Benefit Assessment
The COMP determined that RZ-001 has the potential to satisfy the "significant benefit" requirement for orphan designation even though approved therapies already exist for the condition. That assessment rested on clinical responses and early clinical data observed in patients with recurrent glioblastoma (搜索).
The committee noted that imaging assessments showed sustained tumor regression in multiple patients. Given the aggressive nature of recurrent glioblastoma (搜索), the panel characterized the sustained disappearance of tumors on imaging in a number of patients as notable and clinically meaningful.
Construct and Clinical Program
RZ-001 is an adenovirus type 5-based gene therapy built on Rznomics (搜索)' RNA replacement enzyme technology. It carries an RNA replacement enzyme targeting the mRNA of human telomerase reverse transcriptase (hTERT), which is expressed in cancer cells, together with a herpes simplex virus-derived thymidine kinase (HSV-TK) gene.
The therapy is in Phase 1/2a clinical trials in South Korea and the United States in patients with hTERT-positive recurrent glioblastoma (搜索). A total of 13 patients have been treated: 10 through clinical trials and 3 through the FDA's Expanded Access Program.
Regulatory Incentives if Designation Is Finalized
Once orphan drug designation is finalized, Rznomics (搜索) would secure several regulatory benefits in the EU. The company would gain access to EMA protocol assistance, allowing advance consultation on clinical trial design and on quality, non-clinical and clinical development strategy, along with partial fee waivers during the marketing authorization application process. If marketing authorization is ultimately granted, the company would secure up to 10 years of market exclusivity in the EU for the designated orphan indication.
The COMP recommended that Rznomics (搜索) use EMA protocol assistance during future clinical development to pre-consult on the data needed to demonstrate significant benefit over existing therapies.
Prior US Designation and Company Plans
The European opinion follows the Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA in May of this year for hepatocellular carcinoma (搜索). "Following the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in May of this year for hepatocellular carcinoma (HCC), RZ-001's clinical potential has now been evaluated by another regulatory agency," said Lee Sung-wook, CEO of Rznomics (搜索). "We will pursue indication expansion and business development going forward."
Glioblastoma (搜索) is the most malignant brain tumor among gliomas, with extremely limited treatment options upon recurrence. With the European orphan drug recommendation, RZ-001 is positioned to advance as an anti-cancer gene therapy with simultaneous support from regulators in both the EU and the US.